Genmab A/S (CPH:GMAB)
Denmark
· Delayed Price · Currency is DKK 1,300.00
+4.50 (0.35%)
May 15, 2025, 1:58 PM CET
Genmab Revenue
Genmab had revenue of 715.00M DKK in the quarter ending March 31, 2025, with 18.57% growth. This brings the company's revenue in the last twelve months to 21.64B, up 51.92% year-over-year. In the year 2024, Genmab had annual revenue of 21.53B with 30.67% growth.
Revenue (ttm)
21.64B
Revenue Growth
+51.92%
P/S Ratio
3.71
Revenue / Employee
8.20M
Employees
2,682
Market Cap
80.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 303.14B |
| Coloplast | 27.79B |
| Demant | 22.42B |
| ALK-Abelló | 5.71B |
| H. Lundbeck | 22.00B |
| Zealand Pharma | 55.69M |
| Ambu A/S | 5.83B |
| GN Store Nord | 17.67B |
Genmab News
- 22 hours ago - Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress - Business Wire
- 2 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 5 days ago - Genmab reports Q1 results - Seeking Alpha
- 6 days ago - Genmab Announces Financial Results for the First Quarter of 2024 - GlobeNewsWire
- 10 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 13 days ago - Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - Business Wire
- 13 days ago - Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - GlobeNewsWire
- 17 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire